ASX Stocks Going Ex-Dividend Tomorrow: Australian Clinical Labs (ASX:ACL)

Sonal Goyal

01 September 2026 02:40 PM AEST

ASX Stocks Going Ex-Dividend Tomorrow: Australian Clinical Labs (ASX:ACL)

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Australian Clinical Labs (ASX:ACL) goes ex-dividend on 2 September 2026.
The Dividend is 9.2 cents per share, fully franked, payable on 23 September 2026.
FY26 underlying EBIT increased 1.7%, while underlying NPAT rose 4.3%.
Revenue declined slightly, reflecting weaker market growth and Medicare funding changes.

Dividend Details

Australian Clinical Labs (ASX:ACL) is scheduled to trade ex-dividend on 2 September 2026. Shareholders buying on or after this date will not receive the upcoming payment; eligibility requires holding shares before the ex-date. The dividend is fully franked at 100%, with a payment amount of 9.2 cents per share, due to be paid on 23 September 2026.

Company Update

Australian Clinical Labs released its FY2026 results on 17 August, highlighting improving underlying profitability despite challenging pathology market conditions. Underlying EBIT increased 1.7%, while underlying NPAT rose 4.3%. Revenue declined slightly, reflecting weaker market growth and Medicare funding changes affecting selected tests. The company continues focusing on efficiency, technology, automation and growth opportunities.

Catalysts to Watch

Continued efficiency and automation initiatives within the pathology Business represent a key catalyst, as these appear to be driving profitability improvement even amid revenue softness. Any stabilisation or recovery in pathology test volumes would support the top line. Updates on Medicare funding policy affecting specific test categories are also worth monitoring, given their direct effect on segment revenue. Growth opportunities beyond the core pathology business could provide additional catalysts.

Key Risks

The pathology market has faced weaker growth conditions, and continued softness could keep pressure on revenue even as the company pursues efficiency gains. Medicare funding changes affecting selected tests represent an ongoing Regulatory Risk specific to the sector. Competitive dynamics within Australian pathology and diagnostics also remain a relevant consideration. Automation and technology investments carry execution risk, as realising their intended efficiency benefits depends on successful implementation.

Conclusion

Australian Clinical Labs goes ex-dividend on 2 September 2026, with a fully franked 9.2-cent payment following a FY26 result that showed improving underlying profitability despite a challenging pathology market. Payment is due on 23 September 2026 for eligible shareholders. For investors, the company's efficiency and automation initiatives remain central to its strategy for navigating current market conditions.

Q1: When does Australian Clinical Labs (ASX:ACL) go ex-dividend?

Q2: How much is Australian Clinical Labs' dividend?

Q3: When will the ACL dividend be paid?

Q4: What were Australian Clinical Labs' FY26 results?

Q5: Why did Australian Clinical Labs' revenue decline?

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.